Literature DB >> 19719332

Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.

Bernard Waeber1, François Feihl, Luis M Ruilope.   

Abstract

Recent guidelines recommend initiation of antihypertensive therapy with fixed-dose combinations in high-risk patients because such patients usually need two or more blood pressure (BP)-lowering agents in order to normalize their BP. Agents that block the renin-angiotensin system (ACE inhibitors or angiotensin II receptor antagonists [angiotensin receptor blockers; ARBs]) are preferred for the management of hypertension in most patients exhibiting subclinical target organ damage, or established cardiovascular or renal diseases. Unless contraindicated they should be one of the components of fixed-dose combinations, whereas the other component may be either a calcium channel antagonist or a thiazide diuretic. Fixed-dose combinations containing an ACE inhibitor or ARB plus a calcium channel antagonist appear particularly effective in preventing complications of coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19719332     DOI: 10.2165/11316710-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  104 in total

Review 1.  Compliance with antihypertensive treatment: implications for practice.

Authors:  B Waeber; H R Brunner; J M Métry
Journal:  Blood Press       Date:  1997-11       Impact factor: 2.835

Review 2.  The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal.

Authors:  T F Lüscher; F Cosentino
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

3.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

Review 4.  How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis.

Authors:  Hazel A Bradley; Charles Shey Wiysonge; Jimmy A Volmink; Bongani M Mayosi; Lionel H Opie
Journal:  J Hypertens       Date:  2006-11       Impact factor: 4.844

5.  Optimisation of antihypertensive treatment by crossover rotation of four major classes.

Authors:  J E Dickerson; A D Hingorani; M J Ashby; C R Palmer; M J Brown
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

Review 6.  Calcium antagonists.

Authors:  Ehud Grossman; Franz H Messerli
Journal:  Prog Cardiovasc Dis       Date:  2004 Jul-Aug       Impact factor: 8.194

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

Authors:  Jan A Staessen; Ji-Guang Wang; Lutgarde Thijs
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

9.  Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism.

Authors:  E Perez-Stable; P V Caralis
Journal:  Am Heart J       Date:  1983-07       Impact factor: 4.749

10.  Calcium channel blockade with nitrendipine. Effects on sodium homeostasis, the renin-angiotensin system, and the sympathetic nervous system in humans.

Authors:  F C Luft; G R Aronoff; R S Sloan; N S Fineberg; M H Weinberger
Journal:  Hypertension       Date:  1985 May-Jun       Impact factor: 10.190

View more
  6 in total

Review 1.  Detection and treatment of resistant hypertension.

Authors:  Julian Segura; Alejandro de la Sierra; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2010-10       Impact factor: 5.369

Review 2.  Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.

Authors:  Pedro Marques da Silva
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Fixed and Low-Dose Combinations of Blood Pressure-Lowering Agents: For the Many or the Few?

Authors:  Massimo Leggio; Augusto Fusco; Claudia Loreti; Giorgio Limongelli; Maria Grazia Bendini; Andrea Mazza; Antonio Frizziero; Daniele Coraci; Luca Padua
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

Review 4.  Triple-combination therapy in the treatment of hypertension: a review of the evidence.

Authors:  R Düsing; B Waeber; M Destro; C Santos Maia; P Brunel
Journal:  J Hum Hypertens       Date:  2017-02-23       Impact factor: 3.012

5.  Noradrenergic α₁ receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial.

Authors:  Thomas F Newton; Richard De La Garza; Gregory Brown; Thomas R Kosten; James J Mahoney; Colin N Haile
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

Review 6.  Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.

Authors:  Stefano Omboni; Ettore Malacco; Claudio Napoli; Pietro Amedeo Modesti; Athanasios Manolis; Gianfranco Parati; Enrico Agabiti-Rosei; Claudio Borghi
Journal:  Adv Ther       Date:  2017-03-04       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.